Genomic characterization of metastatic breast cancers

Metastasis is the main cause of death for patients with breast cancer. Many studies have characterized the genomic landscape of breast cancer during its early stages. However, there is evidence that genomic alterations are acquired during the evolution of cancers from their early to late stages, and that the genomic landscape of early cancers is not representative of that of lethal cancers1–7. Here we investigated the landscape of somatic alterations in 617 metastatic breast cancers. Nine driver genes (TP53, ESR1, GATA3, KMT2C, NCOR1, AKT1, NF1, RIC8A and RB1) were more frequently mutated in metastatic breast cancers that expressed hormone receptors (oestrogen and/or progesterone receptors; HR+) but did not have high levels of HER2 (HER2−; n = 381), when compared to early breast cancers from The Cancer Genome Atlas. In addition, 18 amplicons were more frequently observed in HR+/HER2− metastatic breast cancers. These cancers showed an increase in mutational signatures S2, S3, S10, S13 and S17. Among the gene alterations that were enriched in HR+/HER2− metastatic breast cancers, mutations in TP53, RB1 and NF1, together with S10, S13 and S17, were associated with poor outcome. Metastatic triple-negative breast cancers showed an increase in the frequency of somatic biallelic loss-of-function mutations in genes related to homologous recombination DNA repair, compared to early triple-negative breast cancers (7% versus 2%). Finally, metastatic breast cancers showed an increase in mutational burden and clonal diversity compared to early breast cancers. Thus, the genomic landscape of metastatic breast cancer is enriched in clinically relevant genomic alterations and is more complex than that of early breast cancer. The identification of genomic alterations associated with poor outcome will allow earlier and better selection of patients who require the use of treatments that are still in clinical trials. The genetic complexity observed in advanced breast cancer suggests that such treatments should be introduced as early as possible in the disease course.Patient data from six clinical trials are used to compare the genomic landscapes of breast cancer metastases with those of primary tumours, revealing an increase in mutational burden and clonal diversity.

[1]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[2]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[3]  J. Reis-Filho,et al.  Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases , 2018, Oncotarget.

[4]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[5]  L. Chow,et al.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. , 2018, The Lancet. Oncology.

[6]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[7]  Reuben S Harris,et al.  The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer , 2016, Science Advances.

[8]  C. Sotiriou,et al.  Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[10]  M. Heinrich,et al.  Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.

[11]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[12]  J. Reis-Filho,et al.  Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes , 2017, Nature Communications.

[13]  A. Viale,et al.  Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma , 2018, Clinical Cancer Research.

[14]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[15]  C. Sander,et al.  3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets , 2017, Genome Medicine.

[16]  Trevor J Pugh,et al.  Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation , 2013, Nucleic acids research.

[17]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[18]  Ronglai Shen,et al.  Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. , 2018, Cancer cell.

[19]  E. Legius,et al.  Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. , 2016, The Journal of clinical investigation.

[20]  D. Mathews,et al.  Pyrvinium pamoate changes alternative splicing of the serotonin receptor 2C by influencing its RNA structure , 2013, Nucleic acids research.

[21]  N. Socci,et al.  Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.

[22]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[23]  P. Lønning,et al.  Genomic Evolution of Breast Cancer Metastasis and Relapse , 2017, Cancer cell.

[24]  Carlos Caldas,et al.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer , 2015, Nature Communications.

[25]  T. Speed,et al.  Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE" , 2017, PLoS medicine.

[26]  B. Taylor,et al.  deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.

[27]  P. V. van Diest,et al.  Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. , 2018, Cancer research.

[28]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[29]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[30]  Jean Y. J. Wang,et al.  Targeting the RB-pathway in Cancer Therapy , 2010, Clinical Cancer Research.

[31]  N. Navin,et al.  Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.

[32]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[33]  Lajos Pusztai,et al.  Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations , 2017, Nature Communications.

[34]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[35]  Alessandro Pastore,et al.  KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function , 2018, Oncogene.

[36]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[37]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[38]  Jan Schröder,et al.  Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads , 2014, Bioinform..

[39]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[40]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[41]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[42]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[43]  A. Regev,et al.  Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies , 2018, Nature Genetics.

[44]  Benjamin J. Raphael,et al.  CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer , 2015, Genome Biology.

[45]  A. Viale,et al.  Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases , 2017, Clinical Cancer Research.

[46]  E. Mardis,et al.  pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens , 2016, Genome Medicine.

[47]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[48]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[49]  Thomas Bachelot,et al.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.

[50]  Melissa P. Murray,et al.  The Genomic Landscape of Male Breast Cancers , 2016, Clinical Cancer Research.

[51]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[52]  P. Fasching,et al.  Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Lefebvre,et al.  Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis , 2016, PLoS medicine.

[54]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[55]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[56]  Kun Yu,et al.  PureCN: copy number calling and SNV classification using targeted short read sequencing , 2016, Source Code for Biology and Medicine.

[57]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[58]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.